Clindamycin

Contraindicated

Clindamycin Levoketoconazole Recorlev Explained Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Clindamycin Mifepristone Korlym Explained Increased CYP3A4 substrate with NTI exposure Details

Major

Clindamycin Apalutamide Erleada Explained Reduced CYP3A4 substrate exposure Details Clindamycin Asciminib Scemblix Explained Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Clindamycin Avacopan Tavneos Explained Increased exposure to CYP3A4 substrate Details Clindamycin Belzutifan Welireg Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Berotralstat Orladeyo Explained Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Clindamycin Carbamazepine Carbatrol Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Ceritinib Zykadia Explained Increased exposure of CYP3A substrate Details Clindamycin Cholera Vaccine, Live Explained Reduced immune response to the cholera vaccine Details Clindamycin Clarithromycin Biaxin Explained Increased exposure of CYP3A4 substrate and risk for toxicity Details Clindamycin Conivaptan Vaprisol Explained Increased CYP3A substrate exposure Details Clindamycin Crizotinib Xalkori Explained Increased exposure of the CYP3A substrate Details Clindamycin Daridorexant Explained Increased CYP3A4 substrate with NTI exposure Details Clindamycin Elinzanetant Lynkuet Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Clindamycin Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Enzalutamide Xtandi Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Erythromycin Erythrocin Stearate Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Clindamycin Exenatide Bydureon Explained Reduced oral antibiotics absorption and reduced efficacy of oral antibiotics Details Clindamycin Fedratinib Inrebic Explained Increased CYP3A4 substrate exposure Details Clindamycin Fluconazole Diflucan Explained Increased sensitive CYP3A4 substrates exposure Details Clindamycin Gepotidacin Blujepa Explained Increased CYP3A4 substrate with NTI exposure Details Clindamycin Imatinib Gleevec Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Itraconazole Sporanox Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Clindamycin Lanreotide Explained Altered exposure to CYP3A4 substrate Details Clindamycin Lazertinib Lazcluze Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Clindamycin Letermovir Prevymis Explained Increased CYP3A substrate exposure Details Clindamycin Lonafarnib Zokinvy Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Clindamycin Mavorixafor Xolremdi Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Clindamycin Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Clindamycin Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Clindamycin Mitotane Lysodren Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Clindamycin Mobocertinib Exkivity Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Clindamycin Nirogacestat Ogsiveo Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Clindamycin Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Clindamycin Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Pacritinib Vonjo® Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Clindamycin Palbociclib Ibrance Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Clindamycin Phenobarbital Fidoquel Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details